

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Filgotinib for treating moderate to severe rheumatoid arthritis [ID1632]

Final stakeholder list of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Gilead (filgotinib) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Action on Pain • Arthritis Action • Arthritis and Musculoskeletal Alliance • Back Care • Muslim Council of Britain • National Rheumatoid Arthritis Society • Pain Concern • Pain Relief Foundation • Pain UK • South Asian Health Foundation • Specialised Healthcare Alliance • Versus Arthritis <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • British Geriatrics Society • British Institute of Musculoskeletal Medicine • British Orthopaedic Association • British Pain Society • British Society for Rheumatology • British Society of Rehabilitation Medicine • Chartered Society for Physiotherapy • Physiotherapy Pain Association • Primary Care Rheumatology Society • Rheumatoid Arthritis Surgical Society • Royal College of General Practitioners • Royal College of Nursing • Royal College of Occupational Therapists • Royal College of Pathologists • Royal College of Physicians • Royal College of Radiologists • Royal Pharmaceutical Society • Royal Society of Medicine • Society and College of Radiographers • UK Clinical Pharmacy Association <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Welsh Health Specialised Services Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • Abbvie (adalimumab) • Accord Healthcare (methotrexate) • Advanz Pharma (methotrexate) • Amgen (adalimumab biosimilar) • Aspire Pharma (leflunomide) • Biogen (adalimumab biosimilar, etanercept biosimilar, infliximab biosimilar) • Bristol Laboratories (hydroxychloroquine) • Bristol-Myers Squibb (abatacept) • Cipla (methotrexate) • Eli Lilly (baricitinib) • Hospira (methotrexate) • medac (leflunomide, methotrexate) • Merck Sharp & Dohme (golimumab, infliximab) • Mylan (adalimumab biosimilar, leflunomide) • Napp (rituximab biosimilar, infliximab biosimilar) • Nordic Pharma (methotrexate)

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • NHS England • NHS Lambeth CCG • NHS Waltham Forest CCG • Welsh Government 	<ul style="list-style-type: none"> • Orion Pharma (methotrexate) • Pfizer (infliximab biosimilar, tofacitinib, etanercept, methotrexate, sulfasalazine) • Roche (tocilizumab, rituximab) • Rosemont Pharmaceuticals (methotrexate, sulfasalazine) • Sandoz (adalimumab biosimilar, rituximab biosimilar, etanercept biosimilar, infliximab biosimilar methotrexate, leflunomide) • Sanofi (hydroxychloroquine, leflunomide, sarilumab) • Therakind (methotrexate) • UCB Pharma (certolizumab pegol) • Zentiva (hydroxychloroquine, leflunomide) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Bone Research Society • Chronic Pain Policy Coalition • Cochrane Musculoskeletal Group • Genomics England • MRC Clinical Trials Unit • National Institute for Health Research • Orthopaedic Research UK • Pain Relief Foundation • Society of Back Pain Research <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not.

Please let us know if we have missed any important organisations from the lists in the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

¹ Non-company consultees are invited to submit statements relevant to the group they are representing.